Further studies are warranted to elucidate the clinical and/or biological significance of acquired PIK3CA mutations, KRAS mutations and uncommon EGFR (other than p.T790M) mutations as well as other co-existing resistance mutations in TKI-resistant lung cancers. This evidence concerns the gene EGFR and lung cancer.